Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-0509
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model ; volume:11 ; number:1 ; day:19 ; month:7 ; year:2017 ; pages:1-18 ; date:12.2017
BMC systems biology ; 11, Heft 1 (19.7.2017), 1-18, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Lai, Xiulan
- Beteiligte Personen und Organisationen
-
Friedman, Avner
SpringerLink (Online service)
- DOI
-
10.1186/s12918-017-0446-9
- URN
-
urn:nbn:de:1111-201710245678
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lai, Xiulan
- Friedman, Avner
- SpringerLink (Online service)
Ähnliche Objekte (12)
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma